The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Open accessAbstract
Oral daily (2.5 mg) and intermittent ibandronate (between-dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebral fracture. Significant reduction in incident vertebral fracture risk by 62% and 50%, respectively, was shown after 3 years. This is the first study to prospectively show antifracture efficacy for the intermittent administration of a bisphosphonate. Introduction: Bisphosphonates are important therapeutics in postmenopausal osteoporosis. However, they are currently associated with stringent dosing instructions that may impair patient compliance and hence therapeutic efficacy. Less frequent, intermittent administration may help to overcome these deficiencies. This study assessed the efficacy and safety of oral ibandronate administered either daily or intermittently with a dose-free interval of >2 months. Materials and Methods: This randomized, double-blind, placebo-controlled, parallel-group study enrolled 2946 postmenopausal women with a BMD T score ≤ −2.0 at the lumbar spine in at least one vertebra (L1-L4) and one to four prevalent vertebral fractures (T4-L4). Patients received placebo or oral ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months). Results and Conclusions: After 3 years, the rate of new vertebral fractures was significantly reduced in patients receiving oral daily (4.7%) and intermittent ibandronate (4.9%), relative to placebo (9.6%). Thus, daily and intermittent oral ibandronate significantly reduced the risk of new morphometric vertebral fractures by 62% (p = 0.0001) and 50% (p = 0.0006), respectively, versus placebo. Both treatment groups also produced a statistically significant relative risk reduction in clinical vertebral fractures (49% and 48% for daily and intermittent ibandronate, respectively). Significant and progressive increases in lumbar spine (6.5%, 5.7%, and 1.3% for daily ibandronate, intermittent ibandronate, and placebo, respectively, at 3 years) and hip BMD, normalization of bone turnover, and significantly less height loss than in the placebo group were also observed for both ibandronate regimens. The overall population was at low risk for osteoporotic fractures. Consequently, the incidence of nonvertebral fractures was similar between the ibandronate and placebo groups after 3 years (9.1%, 8.9%, and 8.2% in the daily, intermittent, and placebo groups, respectively; difference between arms not significant). However, findings from a posthoc analysis showed that the daily regimen reduces the risk of nonvertebral fractures (69%; p = 0.012) in a higher-risk subgroup (femoral neck BMD T score < −3.0). In addition, oral ibandronate was well tolerated. Oral ibandronate, whether administered daily or intermittently with an extended between-dose interval of >2 months, is highly effective in reducing the incidence of osteoporotic fractures in postmenopausal women. This is the first time that significant fracture efficacy has been prospectively shown with an intermittently administered bisphosphonate in the overall study population of a randomized, controlled clinical trial. Thus, oral ibandronate holds promise as an effective and convenient alternative to current bisphosphonate therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Noninvasive assessment of bone mineral and structure: State of the art
Genant, H. K., Engelke, K., Fuerst, T. P., Glüer, C., Grampp, S., Harris, S. T., Jergas, M. D., Lang, T., Lü, Y., Majumdar, S., et al. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110602 · Cited by 948
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 947
Self-citationStorm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sørensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 926
Flagged first, then by citations
Research works printed but not linked: 4
- Melton, 1991, Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites, J Bone Miner Res, 6, S136
- Kendler, 2002, Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study, Osteoporos Int, 13, S32
- Palmisano, 2002, Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis, Osteoporos Int, 13, S36
- Kiel, 1995, Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures, J Bone Miner Res, 10, 518
Cited by
Sorted by citations
Items 701–800 of 999
Bandeira, F., Dantas, W., & Bilezikian, J. P. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000275 · Cited by 9
Lewiecki, E. M. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.07.003 · Cited by 9
Use of Bisphosphonates in Older Adults: How Long Is Long Enough?
Dunn, R. L., Bird, M. L., Conway, S. E., & Stratton, M. A. (2013) · The Consultant Pharmacist · doi:10.4140/tcp.n.2013.39 · Cited by 9
Mel'nichenko, G. A., Belaya, Z. E., Rozhinskaya, L. Y., Grebennikova, T. A., Pigarova, E. A., Toroptsova, N. V., Nikitinskaya, O. A., Farba, L. Y., Tarbaeva, N. V., Chernova, T. A., et al. (2016) · Osteoporosis and Bone Diseases · doi:10.14341/osteo2016328-36 · Cited by 9
O’Connell, M. B. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.s6-a.s10 · Cited by 9
Diagnosis, Screening and Treatment of Osteoporosis –A Review
Chitra, V., & Evelyn Sharon, S. (2021) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2159 · Cited by 9
Henríquez, M. S., & Romero, M. J. G. D. T. (2009) · Revista Clínica Española · doi:10.1016/s0014-2565(09)70355-8 · Cited by 9
Armbrecht, G., Blenk, T., Chesnut, C. H., Gardner, J. C., Ingersleben, G. V., Mahoney, P., & Felsenberg, D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.10.002 · Cited by 9
Self-citationNonvertebral fracture risk reduction with nitrogen-containing bisphosphonates
Hochberg, M. C. (2008) · Current Osteoporosis Reports · doi:10.1007/s11914-008-0016-6 · Cited by 9
Bala, Y., Kohles, J. D., Recker, R. R., & Boivin, G. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9658-6 · Cited by 9
Self-citationFracture Risk Assessment in Clinical Practice: T-scores, FRAX, and Beyond
Lewiecki, E. M. (2009) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9054-6 · Cited by 9
Ringe, J. D. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s10917 · Cited by 8
Faßbender, W. J., & Stumpf, U. (2006) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-006-0092-x · Cited by 9
Chávez‐Valencia, V., Arce-Salinas, C. A., & Espinosa‐Ortega, F. (2014) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2013.12.001 · Cited by 9
Osteoporosis: el dilema de su definición
Henríquez, M. S. (2005) · Medicina Clínica · doi:10.1157/13072038 · Cited by 9
Epstein, S., Jeglitsch, M., & McCloskey, E. V. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903361307 · Cited by 9
Current and emerging bone resorption inhibitors for the treatment of osteoporosis
Gogakos, A. I., & Anastasilakis, A. D. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451741 · Cited by 9
RETRACTED: Odanacatib for the treatment of postmenopausal osteoporosis
Chapurlat, R. D. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.853038 · Cited by 8
RetractedSecondary fracture prevention: Drug treatment, fall prevention and nutrition requirements
Geusens, P., Lems, W. F., Bours, S., & van den Bergh, J. P. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.04.005 · Cited by 8
The role of the fracture liaison service in the prevention of atypical femoral fractures
Toro, G., Braile, A., Liguori, S., Moretti, A., Landi, G., Cecere, A. B., Conza, G., Cicco, A. D., Tarantino, U., & Iolascon, G. (2023) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x231212747 · Cited by 8
Therapeutic Options for Low Bone Mineral Density in HIV-Infected Subjects
Cotter, A. G., & Mallon, P. W. G. (2012) · Current HIV/AIDS Reports · doi:10.1007/s11904-012-0117-9 · Cited by 9
Osteoporosis: non-hormonal treatment
Rizzoli, R. (2007) · Climacteric · doi:10.1080/13697130701600815 · Cited by 8
Efficacy of ibandronate: a long term confirmation.
Munno, O. D., & Sedie, A. D. (2010) · PubMed Central · Cited by 8
The Effect of Menopause on the Periodontium- A Review
Pullishery, A. A. F. (2015) · JBR Journal of Interdisciplinary Medicine and Dental Science · doi:10.4172/2376-032x.1000170 · Cited by 8
Appropriate use of anabolic treatment for severe osteoporosis.
Adami, S., Brandi, M. L., Canonico, P. L., Minisola, G., Minisola, S., & Tarantino, U. (2010) · PubMed Central · Cited by 8
Vujasinović-Stupar, N., Milic, N. M., Petrović-Rackov, L., Prodanović, N., Mijailović-Ivković, M., Grujic, Z., Bukovic, S., Novkovic, S., Pasalic-Simic, K., Petrovic, V. V., et al. (2010) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh1002056v · Cited by 8
A novel phosphonate for the repair of critical size bone defects
Bassi, A., Gough, J. E., & Downes, S. (2011) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.491 · Cited by 8
Duque, G., & Kiel, D. P. (2009) · Springer eBooks · doi:10.1007/978-1-84628-697-1 · Cited by 8
Bilezikian, J. P., & Rubin, M. R. (2006) · Elsevier eBooks · doi:10.1016/b9-78-012088-5/62650-039x · Cited by 8
New developments surrounding the safety of bisphosphonates
Arum, S. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283184017 · Cited by 8
Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
Derman, R. J. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s5637 · Cited by 8
Treatment of Postmenopausal Osteoporosis
Gupta, G., & Aronow, W. S. (2007) · Comprehensive Therapy · doi:10.1007/s12019-007-0017-x · Cited by 8
Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates
Ringe, J. D., & Farahmand, P. (2006) · Clinical Rheumatology · doi:10.1007/s10067-006-0467-z · Cited by 8
Chapter 20. Age‐Related Bone Loss
Kiel, D. P., Rosen, C. J., & Dempster, D. W. (2008) · Primer on the metabolic bone diseases and disorders of mineral metabolism · doi:10.1002/9780470623992.ch20 · Cited by 8
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature
Mondo, I., Hannou, S., & D’Amelio, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2296543 · Cited by 8
Aslan, A., Özmeriç, A., Bilal, Ö., Doğar, F., Özkaya, Z. S., & Uysal, E. (2014) · Journal of Rheumatology and Orthopedics · doi:10.7243/2055-7000-1-1 · Cited by 6
Effects of minodronate on cortical bone response to mechanical loading in rats
Nagira, K., Hagino, H., Kameyama, Y., & Teshima, R. (2012) · Bone · doi:10.1016/j.bone.2012.11.026 · Cited by 7
Beyond daily dosing: Clinical experience
Cooper, C. C. (2006) · Bone · doi:10.1016/j.bone.2006.01.152 · Cited by 7
Therapeutic holidays in osteoporosis: Long-term strategy of treatment with bisphosphonates
Moro-Álvarez, M. J., Neyro, J. L., & Castañeda, S. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.04.037 · Cited by 7
Robinson, D. E., Ali, M. S., Strauss, V. Y., Elhussein, L., Abrahamsen, B., Arden, N., Ben‐Shlomo, Y., Caskey, F. J., Cooper, C. C., Dedman, D., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25170 · Cited by 8
Kravvariti, E., Kasdagli, M., Diomatari, K. M., Mouratidou, P., Daskalakis, K., Mitsikostas, D. D., Sfikakis, P. P., & Yavropoulou, M. P. (2023) · Osteoporosis International · doi:10.1007/s00198-022-06658-7 · Cited by 8
Cementless Total Knee Arthroplasty
Deans, C., Zitsch, B. P., Kildow, B. J., & Garvin, K. L. (2024) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2024.02.003 · Cited by 7
Ferguson, S., Tepie, M. F., Taylor, A., Roddam, A., Critchlow, C. W., Iqbal, M., Spangler, L., & Bayly, J. (2015) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12422 · Cited by 7
Fracture Risk In Postmenopausal Women
Landis, D. M. (2005) · The Nurse Practitioner · doi:10.1097/00006205-200511000-00011 · Cited by 7
Sequential therapy in the treatment of osteoporosis
Boonen, S., Milisen, K., Gielen, E., & Vanderschueren, D. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.573545 · Cited by 7
Prise en charge optimale des patients présentant une fracture de fragilité
Thomas, T., Féron, J.-M., Delmas, P. D., Kaufman, J. D., Tosi, L. L., Cummings, S. R., Lane, J. M., Johnell, O., & Bouxsein, M. (2006) · Revue de Chirurgie Orthopédique et Réparatrice de l Appareil Moteur · doi:10.1016/s0035-1040(06)75702-6 · Cited by 7
Self-citationBandirali, M., Messina, C., Leo, G. D., Sconfienza, L. M., Aliprandi, A., Ulivieri, F. M., & Sardanelli, F. (2013) · Clinical Radiology · doi:10.1016/j.crad.2013.03.028 · Cited by 7
Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients
Hsu, C., Chiu, W.-C., Chen, J., Chou, C., Su, Y., Yu, S., & Cheng, T. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0621-7 · Cited by 7
Percutaneous Vertebral Body Augmentation: An Updated Review
Omidi-Kashani, F. (2014) · Surgery Research and Practice · doi:10.1155/2014/815286 · Cited by 7
The evidence for antiresorptive osteoporosis treatment in the elderly and old
Maraldo, M. V., Vestergaard, P., McMurdo, M. E. T., & Schwarz, P. (2010) · European Geriatric Medicine · doi:10.1016/j.eurger.2010.08.002 · Cited by 7
Osteoporosis management: translating research into optimal fracture protection II
Singer, A. J., & Boonen, S. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802115887 · Cited by 7
The role of i.v. ibandronate administration in osteoporosis therapy.
Sewerynek, E., & Stuss, M. (2011) · PubMed · Cited by 7
Kobayashi, T., Kaneko, M., & Narukawa, M. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00868-4 · Cited by 7
Long-term strategy in the management of postmenopausal osteoporosis
Rizzoli, R. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.09.003 · Cited by 7
Long-term experience with alendronate in the treatment of osteoporosis
Hochberg, M. C., & Rizzoli, R. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.9.1201 · Cited by 7
Who will benefit from antiresorptive treatment (bisphosphonates)?
Papapoulos, S. E. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.06.009 · Cited by 7
Hou, Y., Gu, K., Xu, C., Ding, H.-Y., Liu, C., & Tuoheti, Y. (2015) · Medicine · doi:10.1097/md.0000000000001007 · Cited by 7
Cole, R. E., & Harris, S. T. (2009) · PubMed Central · Cited by 7
Macías, J. G., & Olmos, J. M. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2022.04.015 · Cited by 6
Ceballos, A., Castaño, G., Mendoza, S., González, J., Más, R., Fernández, L., Illnait, J., Mesa, M., Gámez, R., Fernández, J. C., et al. (2011) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2011.26.2.168 · Cited by 6
Consenso de diagnóstico y tratamiento de la osteoporosis en la mujer posmenopáusica mexicana
Peña-Ríos, D. H., Cisneros-Dreinhofer, F., de la Peña-Rodríguez, M. P., García-Hernández, P. A., Hernández-Bueno, J. A., Jasqui-Romano, S., Mercado-Cárdenas, V. M., Mirassou-Ortega, M., Morales‐Torres, J., Vallejo-Almada, J., et al. (2015) · Medicina Interna de México · Cited by 6
Takeda, S., Sakai, S., Tanaka, K., Tomizawa, H., Serizawa, K., Yogo, K., Urayama, K., Hashimoto, J., Endo, K., & Matsumoto, Y. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0255-6 · Cited by 6
Plate Fixation for Atypical Fractures of the Femoral Diaphysis
Cho, Y.-H., Byun, Y.-S., Jo, S., & Shin, J.-U. (2022) · Clinics in Orthopedic Surgery · doi:10.4055/cios21173 · Cited by 6
Osteoporosis: overview in disease, epidemiology, treatment and health economy.
Pongchaiyakul, C., Songpatanasilp, T., & Taechakraichana, N. (2008) · PubMed · Cited by 6
Long-Term Use of Bisphosphonates in Osteoporosis
Rizzoli, R. (2006) · Women s Health · doi:10.2217/17455057.2.2.309 · Cited by 5
Adami, S., Idolazzi, L., & Rossini, M. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10395651 · Cited by 6
Tratamiento de la osteoporosis
Henríquez, M. S., & Romero, M. J. G. D. T. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70813-3 · Cited by 6
Which Bisphosphonate? It's the Compliance!: Decision Analysis
Lee, Y. J., Park, C. H., Lee, Y., Ha, Y., & Koo, K. (2016) · Journal of Bone Metabolism · doi:10.11005/jbm.2016.23.2.79 · Cited by 6
Nakamura, Y., & Ikegami, S. (2015) · Journal of Nutritional Disorders & Therapy · doi:10.4172/2161-0509.1000188 · Cited by 6
The Effects of Trends in Osteoporosis Treatment on the Incidence of Fractures
Horikawa, A., Miyakoshi, N., Hongo, M., Kasukawa, Y., Shimada, Y., Kodama, H., & Sano, A. (2021) · Journal of Osteoporosis · doi:10.1155/2021/5517247 · Cited by 6
Diab, D. L., Watts, N. B., & Miller, P. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00080-7 · Cited by 7
Osteoporosis: A Therapeutic Update
Mackey, P., & WHITAKER, M. D. (2015) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2015.08.010 · Cited by 6
Yamada, H., Ochi, Y., Mori, H., Nishikawa, S., Hashimoto, Y., Tanaka, M., Deacon, S., & Kawabata, K. (2018) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-018-0968-2 · Cited by 6
Lee, D. R., & Lee, J. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4778-0 · Cited by 6
Diagnostik und Therapie der Osteoporose
Meier, C., & KRAENZLIN, M. E. (2005) · Zeitschrift für Allgemeinmedizin · doi:10.1007/bf03652155 · Cited by 5
Müller, R., & Recker, R. R. (2007) · Bone · doi:10.1016/j.bone.2007.08.004 · Cited by 6
Self-citationLong dosing intervals in the treatment of postmenopausal osteoporosis
Lewiecki, E. M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x233278 · Cited by 6
Hochberg, M. C. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.09.002 · Cited by 6
Risk of Severe Upper Gastrointestinal Complications among Oral Bisphosphonate Users
Ghirardi, A., Scotti, L., Zambon, A., Vedova, G. D., d’Oro, L. C., Lapi, F., Cipriani, F., Caputi, A. P., Vaccheri, A., Gregori, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073159 · Cited by 6
Bisphosphonates for Osteoporosis Prevention and Treatment
Jarvis, C. I., Morin, A. K., & Lynch, A. M. (2005) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1385/bmm:3:1:003 · Cited by 6
Sunyecz, J. A., & Derman, R. J. (2007) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000266070.47052.52 · Cited by 6
Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis
Makras, P., Hamdy, N. A. T., Zwinderman, A. H., Ballieux, B. E. P. B., & Papapoulos, S. E. (2009) · Bone · doi:10.1016/j.bone.2009.01.371 · Cited by 6
Ibandronate: An IV injection for the treatment for postmenopausal osteoporosis
Rizzoli, R., & Reid, D. M. (2007) · Bone · doi:10.1016/j.bone.2007.08.006 · Cited by 6
Cassinat, J. J., & Wright, V. J. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07621-y · Cited by 5
Turner, N., Mayeda, M. S., Lima, B. D., Friess, D., Doung, Y., & Drago, K. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.24.00766 · Cited by 5
Behandlung der Osteoporose mit Bisphosphonaten
Rizzoli, R. (2012) · Therapeutische Umschau · doi:10.1024/0040-5930/a000270 · Cited by 5
Vertebral fractures: evaluation, diagnosis and treatment
Brance, M. L., Cóccaro, N. M., Pastor, M., & Larroudé, M. S. (2020) · Revista Argentina de Reumatología · doi:10.47196/rar.v31i3.397 · Cited by 5
Merugu, C., Sahoo, J., Kamalanathan, S., Ramkumar, G., Reddy, S. V. B., Kar, S. S., Naik, D., Roy, A., Narayanan, N., Patel, D., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03432-5 · Cited by 5
Understanding Osteoporosis: Pathophysiology, Risk Factors, Diagnosis, and Management
Ismail, M. (2024) · Advances in Aging Research · doi:10.4236/aar.2024.133003 · Cited by 5
Appraising osteoporosis care gaps
Olenginski, T. P., Antohe, J. L., Sunderlin, E., & Harrington, T. M. (2011) · Rheumatology International · doi:10.1007/s00296-011-2203-5 · Cited by 5
Nakai, K., Iida, S., Tobinai, M., Hashimoto, J., & Kawanishi, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0206-6 · Cited by 5
Reasons for Bisphosphonate Exclusion in Patients Treated for Osteoporosis
Kamneva, O., Nye, A. M., & Hamrick, I. (2011) · The Consultant Pharmacist · doi:10.4140/tcp.n.2011.325 · Cited by 5
Effect of ibandronate on bending strength and toughness of rodent cortical bone
Savaridas, T., Wallace, R. J., Dawson, S. P., & Simpson, H. (2015) · Bone and Joint Research · doi:10.1302/2046-3758.46.2000311 · Cited by 5
Is treatment of early postmenopausal women with bisphosphonates justified?
Epstein, S. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01366.x · Cited by 5
The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated?
McClung, M. R. (2009) · Salud Pública de México · doi:10.1590/s0036-36342009000700008 · Cited by 5
Brandi, M. L. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.519658 · Cited by 5
Osteoporosis: Prevention and Treatment
Zaheer, S., & LeBoff, M. S. (2016) · Cited by 5
Lu, H., Champlin, R. E., Popat, U., Pundole, X., Escalante, C. P., Wang, X., Qiao, W., Murphy, W. A., & Gagel, R. F. (2016) · BoneKEy Reports · doi:10.1038/bonekey.2016.72 · Cited by 5
Clarke, B. L. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.03.039 · Cited by 5
Team Approach: Preoperative Management of Metabolic Conditions in Total Joint Replacement
Liu, C., Brinkmann, E. J., Chou, S. H.-H., Arias, K. T., Cooper, L., Javedan, H., Iorio, R. R., & Chen, A. F. (2021) · JBJS Reviews · doi:10.2106/jbjs.rvw.21.00112 · Cited by 5
Metadata
- Authors
- Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., Delmas, P. D., & (BONE), F. T. O. I. O. V. F. T. I. N. A. A. E.
- Affiliations
- University of Washington (US)
- Center for Clinical Trials, Bergen, Norway
- Center for Clinical & Basic Research (DK)
- Creighton University (US)
- CECOR AS, Haugesund, Norway
- Oslo Department, Sentrum Røntgen Institut AS, Oslo, Norway
- Universitatsklinikum Benjamin Franklin, Berlin, Germany
- Leverkusen, Germany
- Roche (United Kingdom) (GB)
- F. Hoffmann-La Roche AG (CH)
- Lyon 1 Université (FR)
- Corresponding author
- Chesnut, Charles H
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 19
- Issue
- 8
- Pages
- 1241-1249
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2099054178
- Cited by
- 1,229
- References
- 42
- Citations by year
- 2026: 14 · 2025: 38 · 2024: 20 · 2023: 42 · 2022: 31 · 2021: 37 · 2020: 35 · 2019: 32 · 2018: 32 · 2017: 31 · 2016: 43 · 2015: 45 · 2014: 45 · 2013: 63 · 2012: 62
- FWCI
- 85.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- ibandronate, intermittent dosing, bisphosphonates, postmenopausal osteoporosis, vertebral fractures, fracture risk reduction, bone mineral density, bone turnover, height loss, drug safety, medication adherence, lumbar spine, hip bone density, antifracture efficacy, treatment discontinuation, adverse events
- MeSH terms
- Ibandronic Acid, Aged, Body Height, Bone and Bones, Diphosphonates, Double-Blind Method, Female, Femur, Humans, Lumbar Vertebrae, Middle Aged, Pelvic Bones, Prospective Studies, Risk Factors, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome, Patient Selection, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
